Selexipag

Selexipag

Names
IUPAC name 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide
Other names ACT-293987, NS-304
Identifiers
CAS Number	475086-01-2
ChEBI	CHEBI:90844
ChEMBL	ChEMBL238804
ChemSpider	8089417
IUPHAR/BPS	7552
Jmol interactive 3D	Image
KEGG	D09994
PubChem	9913767
UNII	P7T269PR6S
InChI InChI=1S/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31) Key: QXWZQTURMXZVHJ-UHFFFAOYSA-N InChI=1/C26H32N4O4S/c1-20(2)30(16-10-11-17-34-19-24(31)29-35(3,32)33)23-18-27-25(21-12-6-4-7-13-21)26(28-23)22-14-8-5-9-15-22/h4-9,12-15,18,20H,10-11,16-17,19H2,1-3H3,(H,29,31) Key: QXWZQTURMXZVHJ-UHFFFAOYAA
SMILES CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
Properties
Chemical formula	C26H32N4O4S
Molar mass	496.6 g·mol^−1
Pharmacology
ATC code	B01AC27
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is  ?)
Infobox references

Selexipag (brand name Uptravi) is a drug developed by Actelion for the treatment of pulmonary arterial hypertension (PAH). Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.^[1]

ACT-333679 or MRE-269, the active metabolite of selexipag

History

The US FDA granted selexipag Orphan Drug status for PAH.^[2] It was approved by the US FDA on 22 December 2015.^[2] The expected price for the drug in the US is $160,000 to $170,000 per patient before rebates.^[3]

See also

• Epoprostenol, another name for prostacyclin
• Analogues of prostacyclin:
  • Beraprost
  • Iloprost
  • Treprostinil

References

1. Sitbon, O.; Morrell, N. (2012). "Pathways in pulmonary arterial hypertension: The future is here". European Respiratory Review 21 (126): 321–327. doi:10.1183/09059180.00004812. PMID 23204120.
2. New Drug Approved for Rare Lung Disorder. PPN. 23 Dec 2015 Has link to GRIPHON study results
3. "Actelion sees Uptravi price of $160,000-170,000/patient". Reuters. 2016-01-05. Retrieved 2016-01-06.